KR101556524B1 - Composition for thrombotic disease containing Vitis labruscana extract - Google Patents

Abstract

The present invention relates to a composition for thrombotic diseases containing a Vitis labruscana B. extract. A Vitis labruscana B. extract according to the present invention inhibits platelet aggregation and improves blood circulation by extending blood coagulation time and bleeding time so that it is useful in preventing and treating diseases caused by blood circulation disorders such as arteriosclerosis, cerebral hemorrhage, cardiocerebral apoplexy, cerebral infarction or the like.

Description

TECHNICAL FIELD [0001] The present invention relates to a composition for thrombosis including a leaf extract of Vitis lavrescina,

The present invention relates to a composition for thrombotic diseases comprising a leaf extract of Vitislavus vulgaris.

Blood circulation means that blood circulates the body along the blood vessels around the heart, supplying oxygen and nutrients to each organ and tissues, releasing metabolites, transporting hormones from various endocrine glands to regulate the functions of specific organs, Regulation, osmotic pressure control, and moisture control.

Blood circulation disorder The blood that is pumped out from the heart returns to the heart through the arteries, capillaries, and veins. The blood vessels lose their elasticity and blood clots or cholesterol are deposited on the inner walls of the blood vessels. It says. Blood circulation disorder can cause normal life by causing limbs and limbs, pulling back, neck stiffness, loss of memory, lethargy, weakness of concentration, dizziness and chronic fatigue, resulting in hypertension, arteriosclerosis, heart disease, stroke Therefore, prevention and management are necessary.

In vivo, blood maintains homeostasis by balancing coagulation and dissolution, and its flow is not interrupted under normal conditions. However, when these equilibrium conditions are broken down by various factors, blood flow is disturbed and cardiovascular disease occurs. When collagen on the inner wall of the blood vessel is exposed, platelets in the blood are firstly adhered to and activated and serotonin, adenosine dephosphate (ADP), and thromboxane A2 (thromboxane A2) secreted from platelets Induces aggregation of platelets. Then, the second step is to activate the blood coagulation system of the intrinsic pathway, the extrinsic pathway and the common pathway to rapidly produce the thrombus. Excessive blood clots build up on the walls of the blood vessels, blocking the flow of blood flow and lowering the viscosity of the blood, making the blood circulation unfavorable. This hinders the transfer of oxygen and nutrients into the tissue. In addition, when the blood clot moves along the blood stream and blocks the blood vessels of the heart, lung, and brain, it causes dyspnea and hemoptysis, and causes various types of diseases such as myocardial infarction, pulmonary embolism, and stroke.

Thrombolytic agents, anticoagulants, and antiplatelet agents are currently used for the prevention and treatment of thrombotic diseases. However, aspirin, a typical antiplatelet agent, is known to cause side effects such as gastrointestinal hemorrhage and peptic ulceration. In addition, drugs used as anticoagulants and thrombolytic agents are mostly not orally administered, and their selectivity to thrombosis is low. Thus, when they are taken for a long time, they exhibit various side effects such as hemolysis and abnormal immune response. Therefore, there is a need to develop therapeutic agents that inhibit platelet aggregation and blood coagulation, dissolve thrombi, and minimize side effects.

Currently, the most cultivated grape variety in Korea is Campbell early ( Vitis labruca BAILEY). Campbell, in Ohio, USA, named a breed in 1892 for cultivating and breeding belvidere muscat hamburg ( Vitis vinifera L.) on moore early ( Vitis labruca L.) It was introduced in 1908 in Korea. Minerals rich in grapes are alkaline foods, such as phone sugar, tartaric acid, citric acid, potassium and iron, vitamins A, B1, B2, D and nutrition rich in skin beauty, indigestion and anorexia have been reported to be effective.

The object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of thrombotic diseases comprising, as an active ingredient, an extract of at least one solvent selected from water, alcohol and acetic acid of Vitis labruscana B. leaf .

It is also an object of the present invention to provide a food composition for preventing or ameliorating a thrombotic disease, which comprises an extract of at least one solvent selected from water, alcohol and acetic acid of Vitislavus vulgaris leaves as an active ingredient.

In order to solve the above-mentioned problems, the present invention provides a pharmaceutical composition for preventing or treating thrombotic diseases comprising, as an active ingredient, an extract of at least one solvent selected from water, alcohol and acetic acid of Vitislavus vulgaris leaves to provide.

The present invention also provides a food composition for preventing or ameliorating a thrombotic disease comprising an extract of at least one solvent selected from the group consisting of water, alcohol and acetic acid of Vitislavus vulgaris leaves as an active ingredient.

Hereinafter, the present invention will be described in more detail.

The present invention provides a pharmaceutical composition for preventing or treating thrombotic diseases, which comprises an extract of at least one solvent selected from the group consisting of water, alcohol and acetic acid of Vityslava bruscana leaf as an active ingredient.

The Vitis la Bruiskana is a cross breed of the Moore Early ( Vitis labrusca L.; American species) and Muscat Hamburg ( Vitis vinifera L.; European species) , Generally categorized in the United States and include all cultivated varieties of the United States, such as Campbell, Delaware and Niagara.

 In the case of the extract obtained by extracting the Vityslava brassica leaves with a solvent, the effect of preventing or treating thrombotic diseases is superior to that of the extract of other regions.

 The extract may be extracted by a conventional method in the art, and any one selected from the group consisting of water, alcohol, acetic acid, and combinations thereof may be used. Preferably, water, alcohol, acetic acid, , More preferably 50 vol% aqueous alcohol solution and 3 vol% acetic acid may be mixed and used.

Examples of carriers, excipients and diluents that can be contained in the composition containing the extract of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

The thrombotic disease is not particularly limited as long as it is a disease that can be caused by a problem of blood circulation, and in particular, the extract according to the present invention is useful as a therapeutic agent for preventing or treating a hemorrhage, stroke, cerebral infarction, chronic arterial occlusion, And can be usefully used for one thrombotic disease.

The composition according to the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers for the prevention and treatment of diseases involving thrombus formation.

The composition according to the present invention may further comprise one or more pharmaceutically acceptable carriers in addition to the above-described effective ingredients for administration. The pharmaceutically acceptable carrier may be a mixture of saline, sterilized water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, alcohol and one or more of these components. If necessary, an antioxidant, , And other conventional additives such as a bacteriostatic agent may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Further, it can be suitably formulated according to each disease or ingredient, using appropriate methods in the art or by the method disclosed in Remington's Pharmaceutical Science (recent edition), Mack Publishing Company, Easton PA.

The composition according to the present invention may be administered orally or parenterally (for example, intravenously, subcutaneously, intraperitoneally or topically) according to a desired method, and the dosage may be appropriately selected according to the weight, age, sex, The range varies depending on the condition, diet, time of administration, method of administration, excretion rate and severity of the disease. The daily dose of the mixed extract according to the present invention is 25 to 100 mg / kg, preferably 100 mg / kg, and is preferably administered once to three times a day.

The present invention also provides a food composition for preventing or ameliorating a thrombotic disease comprising an extract of at least one solvent selected from the group consisting of water, alcohol and acetic acid of Vitislavus vulgaris leaves as an active ingredient.

The extract may be extracted by a conventional method in the art, and any one selected from the group consisting of water, alcohol, acetic acid, and combinations thereof may be used. Preferably, water, alcohol, acetic acid, , More preferably 50 vol% aqueous alcohol solution and 3 vol% acetic acid may be mixed and used.

The composition according to the present invention can be added to a health food for the purpose of improving disease caused by a blood circulation disorder. When the extract of the present invention is used as a food additive, the herbal medicine may be mixed and added as it is, Can be used together, and can be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or therapeutic treatment).

There is no particular limitation on the kind of the food. Examples of the food to which the above substance can be added include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gums, ice cream, soups, , Alcoholic beverages and vitamin complexes, and includes all health foods in a conventional sense.

Various additives such as flavors or natural carbohydrates can be used as the food-aid additive of the present invention. The above-mentioned natural carbohydrates are sugar saccharides such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like.

In addition to the above, the composition according to the present invention may further contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid concentrating agents, pH adjusting agents, stabilizers, preservatives, , A carbonating agent used in carbonated drinks, and the like. In addition, the composition according to the present invention may contain flesh for the production of natural fruit juice, fruit juice beverage and vegetable beverage. These components may be used independently or in combination.

The Vitis lavrescus leaf extract according to the present invention inhibits platelet aggregation and prolongs blood coagulation time and bleeding time to improve blood circulation and is useful for the treatment of blood circulation disorders such as arteriosclerosis, cerebral hemorrhage, stroke, And can be usefully used for the prevention and treatment of diseases caused.

FIG. 1 is a graph showing the results of confirming the inhibition of platelet aggregation by treating the platelets of mice of Examples 1 to 5 and Ginkgo biloba extract at various concentrations.
FIG. 2 is a graph showing the results of treatment of the extracts of Examples 1 to 5 and Ginkgo biloba with plasma (0.1, 0.3 and 1 mg / mL) in plasma of a platelet-removing human, followed by treatment with aPPT reagent, Fig. 5 is a graph showing a result of measuring time. The vertical axis of the graph represents the solidification time (sec).
FIG. 3 is a graph showing the results of confirming the ability of the experimental animals to inhibit platelet aggregation after oral administration of Example 4, Example 5 and Ginkgo biloba extract to experimental animals at different concentrations. The new axis of the graph represents the relative value of the degree of agglutination of the experimental group to the control group, and the abscissa of the graph represents the dose (mg / kg) of each of the experimental groups, Vitislavus vulgaris and Ginkgo biloba extract.
FIG. 4 is a graph showing the result of measuring the tail bleeding time of experimental animals by treating the extracts of Example 4, Example 5, The vertical axis of the graph represents the relative value of the bleeding time of the experimental group to the control group, and the horizontal axis of the graph represents each experimental group.

It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit or scope of the present invention as defined by the appended claims. It will be obvious to you.

Examples. Vitis la Bruiskana leaf ( Vitis labruscana B.) Extract preparation

In order to obtain an extract of Vityslava brassica leaves according to the kind and content of the extracting solvent, extraction of Vityslava bruciana leaves was carried out as follows.

More specifically, the leaves of Vitis la Bruciana were washed with water to remove foreign matters, followed by drying and pulverization. An extract of Vitysulla brucus canana leaves was obtained by the method of Examples 1 to 5 using the above-mentioned pulverized Vitislava bruscuna leaf.

In Example 1, 2 L of purified water was added as an extraction solvent to 100 g of the B. t.bruskana leaf ground in the above. And the mixture was repeated twice at 90 캜 for 3 hours to extract the Vityslava brassica leaves using a reflux cooling method. The extract was filtered, concentrated under reduced pressure in a water bath at 40 ° C, and dried The final Vitis lavrescina leaf extract was obtained.

In Example 2, an extract was obtained in the same manner as in Example 1 except that purified water and 3% by volume of acetic acid were mixed as an extraction solvent.

In Example 3, an extract was obtained in the same manner as in Example 1 except that 30% by volume of an alcohol aqueous solution and 3% by volume of acetic acid were mixed as an extraction solvent.

Example 4 was obtained in the same manner as in Example 1 except that 50% by volume of an aqueous alcohol solution was used as the extraction solvent.

In Example 5, an extract was obtained in the same manner as in Example 1 except that 50% by volume of an aqueous alcohol solution and 3% by volume of acetic acid were used as extraction solvents.

As a result of the above extraction, it was found that 19.0% of Example 1, 28.2% of Example 2, 25.8% of Example 3, 20.1% of Example 4, 19.0% of Vitisla brucina Leaf extract yield was confirmed.

EXPERIMENTAL EXAMPLE 1. Comparison of Platelet Aggregation Inhibitory Effect of Vitis lavrucina leaf Extract

In order to comparatively measure the platelet aggregation inhibitory effect of the Vityslava brassica leaf extract obtained according to Examples 1 to 5, the following experiment was conducted.

More specifically, the experimental rat (Rat) was anesthetized with ether, and a PT containing 3.2% sodium citrate, which is an anticoagulant, and the blood of the experimental rats at a ratio of 1: 9 (v / v) Blood was drawn from the abdominal artery of the experimental rats using a tube. The collected blood was centrifuged at 200 xg for 10 minutes to separate the supernatant and obtain platelet rich plasma (PRP). Then, the supernatant was separated and the remaining portion was centrifuged at 800 xg for 15 minutes and the supernatant was separated to obtain a platelet poor plasma (PPP). Platelet counts were then measured using a platelet cell counter (Horiba LC-660, Japan) and the platelets were diluted to 4 × 10 ⁸ platelets / mL using the PPP. Platelets aggregated at low temperatures, so all experiments were performed at room temperature. The inhibition rate of platelet aggregation in rats was confirmed by turbidity measurement through Aggregometer (Chrono-log, Haver town, PA, USA). The PRP was preserved at 37 캜 for 5 minutes, and then the Vityslava brassica leaf extracts of Examples 1 to 5 obtained in Example 1 and a Ginkgo biloba extract known to be effective for improving blood circulation were used as a sample 0.1, 0.3, and 1 mg / mL, respectively. 2 minutes later, adenosine diphosphate (ADP) (5 μl), which is a platelet aggregation inducer (agonist), was induced. PRP not treated with the sample was expressed as a normal group and expressed by the following formula (1). The results are shown in Table 1 and Fig.

sample Treatment concentration (mg / mL) Coagulation inhibition rate (%) Ginkgo biloba 0.1 - 0.3 9.41 ± 1.28 One 20.89 ± 7.51 Example 1 0.1 - 0.3 1.2 ± 2.31 One 15.0 + 1.94 Example 2 0.1 - 0.3 1.6 ± 2.28 One 7.4 ± 8.31 Example 3 0.1 - 0.3 4.0 ± 5.70 One 12.1 ± 3.42 Example 4 0.1 - 0.3 3.88 ± 3.16 One 23.36 ± 5.99 Example 5 0.1 3.14 ± 3.01 0.3 11.96 ± 6.37 One 43.04 + - 7.07

As shown in Table 1 and Fig. 1, the platelet aggregation effect induced by ADP when treated at a concentration of 0.1 mg / mL was found in all of Examples 1 to 5, though there was a difference in the concentration of the extracts. It was confirmed that the extract of Example 5 exhibited a platelet aggregation inhibitory effect about twice as high as that of the other treatments. Therefore, it was confirmed that the extract of Vitis lavrescina leaf has platelet aggregation effect, but especially when the extraction solvent is limited as in Example 5, it has a remarkably excellent inhibitory effect.

Experimental Example 2: Confirmation of blood coagulation route according to Examples 1 to 5

In order to determine which pathway of endogenous and exogenous pathways participates in blood coagulation by the treatment of Examples 1 to 5, the following experiment was conducted.

Experimental Example 2-1. Measurement of coagulation time by extrinsic pathway

More specifically, plasma of a person completely removed from the platelets was heated at 37 ° C in advance, treated with Vitoslava brassica leaf extracts of Examples 1 to 5 obtained in Example 1 and a control group of Ginkgo biloba extract, and stored for 5 minutes Respectively. Then, PT reagent (TECO, Germany) heated to 37 ° C was quickly dispensed, and the time until coagulation was achieved by pressing the timer was measured using a core coagulometer (Coatron M4, Germany) (Prothrombin time, PT) were measured and expressed as the mean ± standard deviation. The results are shown in Table 2 below.

sample Concentration (mg / mL) PT (sec) Normal group - 17.8 ± 0.21 Ginkgo biloba 0.1 16.9 + 0.14 0.3 17.5 ± 0.67 One 17.6 ± 0.34 Example 1 0.1 17.3 ± 0.17 0.3 17.7 + 0.44 One 18.0 + - 0.68 Example 2 0.1 17.3 + 1.01 0.3 18.1 ± 0.32 One 18.3 ± 0.17 Example 3 0.1 17.9 ± 0.61 0.3 17.7 ± 0.21 One 18.2 ± 0.42 Example 4 0.1 17.6 ± 0.27 0.3 17.5 ± 0.10 One 17.9 ± 0.53 Example 5 0.1 17.8 + 0.49 0.3 17.2 ± 0.21 One 18.1 ± 0.12

As shown in Table 2, it was confirmed that there was almost no change in the prothrombin time (PT) in all the experimental groups as compared with the normal group.

Thus, it was confirmed that Ginkgo biloba and Vitilus brucus leaf extracts of Examples 1 to 5 had little effect on exogenous coagulation factors.

Experimental Example 2-2. Measurement of coagulation time by intrinsic pathway

More specifically, plasma of a person completely removed from the platelets was heated at 37 ° C in advance, treated with Vitoslava brassica leaf extracts of Examples 1 to 5 obtained in Example 1 and a control group of Ginkgo biloba extract, and stored for 5 minutes Respectively. The aPTT reagent (TECO, Germany), which had been heated to 37 ° C, was added thereto, followed by further incubation for 5 minutes. Then, the calcium chloride solution (CaCl ₂ ) was quickly dispensed and the time until the coagulation was achieved by pressing the timer was measured using an activated partial thromboplastin time (aPTT) using a coacron meter (Coatron M4, Germany) ) Were measured and expressed as the mean ± standard deviation. The results are shown in Table 3 and FIG.

sample Concentration (mg / mL) aPTT (sec) Normal group - 45.1 ± 0.49 Ginkgo biloba 0.1 44.5 ± 1.16 0.3 47.5 ± 0.29 One 47.5 ± 0.78 Example 1 0.1 44.9 ± 0.36 0.3 53.1 ± 0.60 One 53.6 ± 1.08 Example 2 0.1 49.0 + - 0.58 0.3 50.0 + - 0.64 One 53.8 ± 0.92 Example 3 0.1 46.5 ± 0.26 0.3 50.0 + - 0.85 One 51.1 ± 0.25 Example 4 0.1 45.4 ± 0.71 0.3 46.6 ± 0.92 One 46.7 ± 1.99 Example 5 0.1 43.6 ± 0.69 0.3 50.8 ± 0.61 One 63.5 ± 1.31

As shown in Table 3 and FIG. 2, when the treatment was carried out at a concentration of 1 mg / mL treated with Vitis lavrucina leaf extract, the blood coagulation time due to the endogenous coagulation mechanism was increased compared with the normal group, It was confirmed that the blood coagulation time of Example 5 was significantly increased compared to that of Ginkgo biloba extract and Examples 1 to 4.

Therefore, it was confirmed that the Vittyla brucus canana leaf extract has an effect of inhibiting blood coagulation by increasing the aPTT time in which the endogenous factor participates. In particular, it was confirmed that the blood coagulation inhibitory ability of Example 5 is remarkably excellent.

Experimental Example 3. Assessment of inhibition of platelet aggregation in experimental animals

Experimental Example 3-1. Improvement of blood circulation of Vitis lavrucina leaf extract in experimental animals

Using Examples 4 and 5, which are most effective in the in vitro experiments of Examples 1 and 2, blood circulation improvement effect was confirmed in the experimental animals.

More specifically, male rats (7 weeks old, weighing 300-320 g) were supplied from Orient Bio (Seong-nam si, Korea), and the temperature of the feeding room was 22 ± 2 ℃ and the humidity was 40 ~ 60 , And the night and day cycle was 12 hours at 6:00 am and 6:00 pm. The standard feed and water were freely accessible and adapted to the environment for one week before the experiment. Ginkgo biloba extract (Comparative Example) and Example 4 and Example 5 were dissolved in water and administered orally once a day at the same time every day for one week. On the last day of the experiment, rats were anesthetized with ether and blood was drawn from the abdominal aorta using a PT tube containing 3.2% sodium citrate as an anticoagulant in a ratio of 1: 9 (v / v) to blood. The obtained blood was centrifuged at 200 × g for 10 minutes, and the supernatant was separated to prepare PRP. The remaining portion was centrifuged at 800 × g for 15 minutes, and the supernatant was separated to obtain PPP. Platelet counts were then measured using a platelet cell counter (Horiba LC-660, Japan) and diluted to 4 × 10 ⁸ platelets / mL using PPP. Platelets aggregated at low temperatures, so all experiments were performed at room temperature. The inhibition rate of platelet aggregation in rats was confirmed by turbidity measurement through a whole blood coagulation analyzer (Chrono-log, Haver town, PA, USA). The PRP isolated from the experimental animals was preserved at 37 ° C for 2 minutes and then induced with ADP (5 μl) as a platelet aggregation inducer. The PRP of the experimental animals without oral administration of the sample was used as the normal group, Respectively. The results are shown in Table 4 and FIG.

sample Concentration (mg / kg) Coagulation inhibition rate (%) Ginkgo biloba 40 23.0 ± 3.84 Example 4 25 12.4 ± 6.55 50 20.8 ± 5.65 100 24.9 ± 3.94 Example 5 25 19.1 ± 9.56 50 29.8 ± 3.49 100 39.6 ± 4.99

As shown in Table 4 and FIG. 3, platelet aggregation rate by ADP for 1 week in experimental animals was significantly higher than that of Example 5 in comparison with Ginkgo biloba extract (Comparative Example) and ADP-induced platelets It was confirmed that the effect of suppressing aggregation was excellent. Therefore, it was confirmed that the extract of Example 5 had remarkably superior effects than other extracts in vivo .

Experimental Example 3-2. Comparison of the effects of Vitis lavrescan leaf on tail bleeding in experimental animals

To measure the ability of platelets and blood clotting factors to form a hemostatic plug, the tail bleeding time of the experimental animals was measured as follows.

More specifically, experimental rats dosed for one week were anesthetized by intraperitoneal injection of a mixture of rumun (20 mg / kg) and ketamine (75 mg / kg). Thereafter, the mice were placed on a flat surface so that the temperature was not lowered, the tail was vertically slackened, and 3 mm was cut from the tip, and the time for which the blood was soaked in physiological saline maintained at 37 ° C was measured. Bleeding time was observed for up to 20 minutes if blood was not taken for more than 30 seconds. The results are shown in Table 5 and FIG.

sample Concentration (mg / kg) Bleeding time (sec) Normal 720 ± 129 Ginkgo biloba Administered group 25 765 ± 130 Example 4 Administration group 25 683 ± 115 50 680 ± 113 100 723 ± 146 Example 5 Administration group 25 687 ± 43 50 881 ± 199 100 1051 ± 113

As shown in Table 5 and FIG. 4, when administered to experimental animals for one week, there was almost no change in bleeding time according to the concentration in Example 4 administration group. However, when the administration of Example 5 was performed, the bleeding time was significantly increased depending on the concentration. When administered at 50 and 100 mg / kg, the bleeding time was extended about 1.5 times or more more than that of Example 4 and the Ginkgo biloba extract- .

Therefore, the composition for improving blood circulation using the Vitis lavrucus leaf extract according to the present invention inhibits platelet aggregation caused by ADP without side effects and has an effect of improving blood circulation by prolonging blood clotting time and bleeding time in vivo Extracts.

Formulation Example 1. Preparation of a pharmaceutical composition

1-1. Manufacture of Powder

Leaf Extract of Vitesse Bruiskana 20 mg

Lactose 100 mg

Talc 10 mg

The above components are mixed and filled in airtight bags to prepare powders.

1-2. Manufacture of tablets

Leaf extract of Vitesse Bruiskana 10 mg

Corn starch 100 mg

Lactose 100 mg

Magnesium stearate 2 mg

After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.

1-3. Preparation of capsules

Leaf extract of Vitesse Bruiskana 10 mg

Crystalline cellulose 3 mg

Lactose 14.8 mg

Magnesium stearate 0.2 mg

The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.

1-4. Injection preparation

Leaf extract of Vitesse Bruiskana 10 mg

180 mg mannitol

Sterile sterilized water for injection 2974 mg

Na ₂ HPO ₄ 2H ₂ O 26 mg

(2 ml) per 1 ampoule in accordance with the usual injection preparation method.

1-5. Manufacture of liquid agent

Leaf Extract of Vitesse Bruiskana 20 mg

10 g per isomer

5 g mannitol

Purified water quantity

Each component was added and dissolved in purified water according to the usual liquid preparation method, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was added with purified water to adjust the total volume to 100 ml, And sterilized to prepare a liquid preparation.

Formulation Example 2. Preparation of Food Composition

2-1. Manufacture of health food

Vitesse Bruiskana leaf extract 100 mg

Vitamin mixture quantity

70 [mu] g of vitamin A acetate

Vitamin E 1.0 mg

Vitamin B1 0.13 mg

0.15 mg of vitamin B2

Vitamin B6 0.5 mg

0.2 [mu] g vitamin B12

Vitamin C 10 mg

Biotin 10 μg

Nicotinic acid amide 1.7 mg

50 ㎍ of folic acid

Calcium pantothenate 0.5 mg

Mineral mixture quantity

1.75 mg of ferrous sulfate

0.82 mg of zinc oxide

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Secondary calcium phosphate 55 mg

Potassium citrate 90 mg

Calcium carbonate 100 mg

Magnesium chloride 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.

2-2. Manufacture of health drinks

Vitesse Bruiskana leaf extract 100 mg

Vitamin C 15 g

Vitamin E (powder) 100 g

19.75 g of ferrous lactate

3.5 g of zinc oxide

Nicotinic acid amide 3.5 g

Vitamin A 0.2 g

Vitamin B1 0.25 g

Vitamin B2 0.3 g

Water quantification

The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 DEG C for about 1 hour. The solution thus prepared was filtered and sterilized in a sterilized 2 liter container, It is used in the production of the health beverage composition of the invention.

Although the compositional ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the compounding ratio according to the regional or national preference such as the demand class, the demanding country, and the use purpose.

Claims (5)

Prevention or prevention of thrombotic diseases comprising an extract of Vitis labruscana B. leaf extracted with a mixed solvent containing 40 to 60% by volume of alcohol and 1 to 5% by volume of acetic acid as an active ingredient. A pharmaceutical composition for therapeutic use.
delete The method according to claim 1,
Wherein the thrombotic disease is any one selected from the group consisting of arteriosclerosis, cerebral hemorrhage, stroke, cerebral infarction, chronic arterial occlusion, and combinations thereof. Prevention or prevention of thrombotic diseases comprising an extract of Vitis labruscana B. leaf extracted with a mixed solvent containing 40 to 60% by volume of alcohol and 1 to 5% by volume of acetic acid as an active ingredient. Food composition for improvement.
delete

Images